Matricelf

Company Overview

Snapshot

Founded in April 2019, Matricelf operates with 11–50 employees. The company has raised over $10 million across four funding rounds from two investors. Matricelf went public on the TASE in June 2021, raising $7.4 million.

Business overview

Matricelf is a biotechnology company focused on developing personalized autologous regenerative medicine. The company's core technology involves producing engineered tissue from a patient's omental biopsies, utilizing a proprietary decellularization process to separate stromal cells and extracellular matrix (ECM). This ECM is then used to create a thermo-responsive hydrogel, into which reprogrammed induced pluripotent stem cells (iPSCs) are incorporated and differentiated into functional tissue. Matricelf's platform aims to treat a range of medical conditions, including spinal cord injuries, age-related macular degeneration, Parkinson's disease, and myocardial infarction, serving the healthcare and life sciences sectors.

Strategic signal

Matricelf is demonstrating strong progress in its clinical development pipeline, particularly for spinal cord injury treatments. In June 2026, the company advanced towards its first-in-human trial by initiating a GMP manufacturing program and completing a successful GLP safety study. This indicates a significant step forward in translating its regenerative medicine platform from preclinical stages to human clinical application, signaling to investors a robust and accelerating path towards commercialization and therapeutic impact.

Company Intelligence Q&A

What is Matricelf's primary focus in regenerative medicine?

Matricelf focuses on developing personalized autologous regenerative medicine, utilizing a patient's own cells and matrix to create engineered tissues for therapeutic applications.

When did Matricelf go public?

Matricelf went public on the TASE in June 2021, raising $7.4 million.

What was a significant recent development regarding Matricelf's spinal cord implant?

In March 2026, Matricelf reported positive RNA sequencing results demonstrating a promising safety profile for its personalized spinal cord implant.

Has Matricelf formed any strategic collaborations recently?

In March 2026, Matricelf entered a strategic collaboration with Japan's CiRA Foundation to advance next-generation regenerative manufacturing.

What is Matricelf's recent progress towards human trials for spinal cord injury?

In June 2026, Matricelf initiated a GMP manufacturing program and completed a successful GLP safety study, advancing towards its first-in-human trial for spinal cord injury.